XSpray Pharma AB (OSTO:XSPRAY) Total Tax Payable: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:XSPRAY XSpray Pharma AB OSTO:XSPRAY
28 GF Score
Price kr10.02
View Full Analysis

What is XSpray Pharma AB Total Tax Payable?

XSpray Pharma AB OSTO:XSPRAY 28 Total Tax Payable is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:XSPRAY with a GF Score™ of 28/100.

XSpray Pharma AB's Total Tax Payable for the quarter that ended in Jun. 2026 was kr0.00 Mil.

XSpray Pharma AB's quarterly Total Tax Payable declined from Dec. 2025 (kr2.62 Mil) to Mar. 2026 (kr0.00 Mil) but then stayed the same from Mar. 2026 (kr0.00 Mil) to Jun. 2026 (kr0.00 Mil).

XSpray Pharma AB's annual Total Tax Payable increased from Dec. 2023 (kr2.38 Mil) to Dec. 2024 (kr2.49 Mil) and increased from Dec. 2024 (kr2.49 Mil) to Dec. 2025 (kr2.62 Mil).

XSpray Pharma AB Total Tax Payable Related Terms

XSpray Pharma AB Total Tax Payable Historical Data

* Premium members only.

The historical data trend for XSpray Pharma AB's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Total Tax Payable Chart

XSpray Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 2.06 2.38 2.49 2.62

XSpray Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 2.62 0.00 0.00
OSTO:XSPRAY
28GF Score
XSpray Pharma AB OSTO:XSPRAY
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of kr0.00 Mil mean?
XSpray Pharma AB (OSTO:XSPRAY) has a Total Tax Payable of kr0.00 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on XSpray Pharma AB and its competitors.
Is XSpray Pharma AB's Total Tax Payable too high?
XSpray Pharma AB's current Total Tax Payable is kr0.00 Mil. Overall, XSpray Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Total Tax Payable compare to VRTX and REGN?
XSpray Pharma AB's Total Tax Payable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current Total Tax Payable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (OSTO:XSPRAY) has a current Total Tax Payable of kr0.00 Mil. The current Total Tax Payable is kr0.00 Mil. XSpray Pharma AB's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For XSpray Pharma AB (OSTO:XSPRAY), the current Total Tax Payable is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges 0GHZ:UK6XP:Germany
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
28GF Score

Get the complete analysis for OSTO:XSPRAY

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.02
Price